Pancreatic Cancer Stage IIB

What Stage IIB Means

T1-3, N1, M0 — Tumor any size with regional lymph node metastases, no distant metastases. Resectable or borderline resectable depending on vascular involvement.

Treatment Approach for Stage IIB

Neoadjuvant FOLFIRINOX for 2 months, restaging, then surgical resection if resectable. Adjuvant therapy continuation. Borderline resectable cases benefit from neoadjuvant therapy.

Survival Rates and Prognosis

The 5-year survival rate for pancreatic cancer at Stage IIB is approximately 5-year survival: 5-9% in surgical series. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage IA	5-year survival: 14-20% in surgical series	Surgical resection (Whipple or distal pancreatectomy) followed by adjuvant…
Stage IB	5-year survival: 12-16% in surgical series	Surgical resection (Whipple or distal pancreatectomy) followed by adjuvant…
Stage IIA	5-year survival: 7-12% in surgical series	Neoadjuvant FOLFIRINOX preferred, then surgical resection if response adequate….
Stage III	5-year survival: 2-5% (median OS ~12-15 months with chemotherapy)	Neoadjuvant FOLFIRINOX for 4-6 months with reassessment for resectability. If…
Stage IV	5-year survival: <5% (median OS ~6-9 months with FOLFIRINOX, ~8-10 months with gemcitabine/nab-paclitaxel)	Palliative systemic chemotherapy: FOLFIRINOX for fit patients (ECOG PS 0-1),…